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Background: Current Medical Research Council (MRC) guidance on complex interventions advocates pilot trials and
feasibility studies as part of a phased approach to the development, testing, and evaluation of healthcare
interventions. In this paper we discuss the results of a recent feasibility study and pilot trial for a randomized
controlled trial (RCT) of pelvic floor muscle training for prolapse (ClinicalTrials.gov: NCT01136889). The ways in which
researchers decide to respond to the results of feasibility work may have significant repercussions for both the
nature and degree of tension between internal and external validity in a definitive trial.
Methods: We used methodological issues to classify and analyze the problems that arose in the feasibility study.
Four centers participated with the aim of randomizing 50 women. Women were eligible if they had prolapse of any
type, of stage I to IV, and had a pessary successfully fitted. Postal questionnaires were administered at baseline, 6
months, and 7 months post-randomization. After identifying problems arising within the pilot study we then
sought to locate potential solutions that might minimize the trade-off between a subsequent explanatory versus
pragmatic trial.
Results: The feasibility study pointed to significant potential problems in relation to participant recruitment,
features of the intervention, acceptability of the intervention to participants, and outcome measurement. Finding
minimal evidence to support our decision-making regarding the transition from feasibility work to a trial, we
developed a systematic process (A process for Decision-making after Pilot and feasibility Trials (ADePT)) which we
subsequently used as a guide. The process sought to: 1) encourage the systematic identification and appraisal of
problems and potential solutions; 2) improve the transparency of decision-making processes; and 3) reveal the
tensions that exist between pragmatic and explanatory choices.
Conclusions: We have developed a process that may aid researchers in their attempt to identify the most
appropriate solutions to problems identified within future pilot and feasibility RCTs. The process includes three key
steps: a decision about the type of problem, the identification of all solutions (whether addressed within the
intervention, trial design or clinical context), and a systematic appraisal of these solutions.
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Over the past 15 years, there has been increasing formal
guidance and a growing number of methodological pa-
pers, opinions, and commentaries published highlighting
the need for greater attention to be paid to both the
initial development of healthcare interventions and the
design of their evaluation [1-3]. Such attention is under-
standable given both the increasing cost associated with
delivering high quality trials [4], the number of interven-
tions that fail to demonstrate effectiveness, and the diffi-
culties in translating any demonstrable benefits into
real-world contexts [5]. There have been suggestions
that many of these translational issues may be ame-
liorated by addressing transferability to practice issues
within earlier stages of intervention design [6-8].
Common recommendations include the need for thor-
ough feasibility work to be conducted in order to pre-
empt problems with the intervention itself, to support
the implementation of a robust trial or other evaluative
design, and for transferability to real-world practice. For
example, current Medical Research Council (MRC) guid-
ance on complex intervention evaluation advocates two
distinct processes as part of a phased approach to the
development, evaluation, and implementation of com-
plex interventions in healthcare [1,2]. This includes
feasibility studies (asking questions about whether the
study can be done) and pilot trials (a miniature version
of the main trial), which aim to test aspects of study
design and processes for the implementation of a larger
main trial in the future [2,9,10]. This increasingly de-
tailed preparatory stage aims to maximize the likelihood
of delivering a definitive trial that is high in terms of
both internal validity (the scientific robustness of the
trial) and external validity (its generalizability to routine
real-world contexts). Simultaneously achieving both in-
ternal and external validity may be problematic; indeed,
they may be in tension [11,12]. Consequently, two cat-
egories of trial have entered the methodological language
[13,14]: explanatory trials, which focus on establishing
efficacy (that is, can the intervention work?) with result-
ant high internal but low external validity; and pragmatic
trials, which focus on effectiveness (that is, does the
intervention work in real-world contexts?) with resultant
lower internal but higher external validity.
Despite the recognized importance of feasibility and
pilot work, two problems exist. First, several authors have
suggested that the results of most contemporary pilot
trials or feasibility studies are published with a focus on
outcomes [9,15,16] rather than the methodological issues
which these studies are commonly intended to investigate.
Such studies may fail to detect or address any of the
subsequent threats to internal or external validity, and
certainly do not have sufficient sophistication to identify
trade-offs or potential solutions. Second, the reporting ofpilot trials and feasibility studies may be sub-optimum.
Given their importance, such studies ought to be carefully
designed, with clear aims and objectives to support their
own scientific validity in order to appropriately inform
decisions regarding any future trial [16,17]. Yet in a recent
review of published pilot trials and feasibility studies only
56% of the identified studies reported issues that would be
useful in the development of a main trial [15].
In this paper we present an example of a feasibility
study, which included a pilot trial, of a complex inter-
vention. We reflect upon the importance of feasibility
work and how a better understanding of the processes of
developing the definitive trial following a feasibly study
or pilot trial might contribute to the debate regarding
explanatory and pragmatic trials. We discuss the meth-
odological implications for future feasibility study con-
duct and reporting. The example relates to a complex
intervention for the conservative management of female
pelvic organ prolapse. It was hypothesized that un-
dertaking pelvic floor muscle training (PFMT) with a
vaginal pessary in place would lead to additional im-
provements in prolapse symptoms and quality of life for
women with prolapse beyond that expected from a
pessary alone. PFMT and pessaries are commonly used
independently to treat pelvic organ prolapse [18,19].
There is growing level one evidence to support the ef-
fectiveness of PFMT [20,21]. In addition, some research
suggests that use of a pessary may improve the anatom-
ically defined stage of prolapse [22], and a woman’s
symptoms and quality of life [23-25]. However, there is
no evidence relating to the combination of these treat-
ments, and whether a combination is more effective for
prolapse than treatment with either alone.
Due to the complex nature of PFMT, which involves
multiple patient/therapist contacts and a progressive
tailored home exercise programme, there was a need to
consider evaluation of the PFMT plus pessary interven-
tion in the light of the MRC’s framework for evaluation
of complex interventions [2]. Furthermore, while there
were some aspects of design which could be confidently
determined based on previous research in this clinical
area (for example, the primary outcome measure had
been developed and tested [26]), there were other as-
pects of the design for which evidence was lacking, and
therefore a feasibility study, including a pilot trial, was
deemed necessary prior to undertaking a definitive trial.
The aims of this feasibility study and pilot trial were:
to determine the feasibility of conducting an RCT of the
effectiveness of a PFMT intervention in addition to a va-
ginal pessary versus a vaginal pessary alone in improving
prolapse symptoms, quality of life, and prolapse severity
(including assessing issues of eligibility, checking all
components of the intervention work together); and to
develop and test the methods for a main trial (including
Bugge et al. Trials 2013, 14:353 Page 3 of 13
http://www.trialsjournal.com/content/14/1/353sample size calculations, eligibility, recruitment, consent,
randomization, adherence to the intervention, partici-
pant retention, logistics of a multicenter randomized
controlled trial (RCT)).
The aims of this paper are: to outline the processes we
used to explore the best pathway forward from feasibility
study and pilot trial to main trial and ‘real-world’ im-
plementation; to describe a process designed to assist
researchers in making best use of the findings from their
feasibility and pilot work to inform their subsequent
decisions regarding a follow-on trial; and to illustrate the
use of the process using an exemplar feasibility study,
the Pessary Plus Physiotherapy for Pelvic Organ Prolapse
(PEPPY) study.
Methods
PEPPY feasibility study and pilot trial methods
The research design assessed both issues of feasibility
and issues of implementation for the main trial. We
assessed feasibility through progress in the pilot trial
rather than separately. In hindsight, qualitative methods
would have been a useful addition to allow exploration
of clear difficulties that subsequently arose.
Four centers were involved in recruiting pilot trial
women who were new outpatient attendees at gynecology
clinics with symptomatic prolapse and fitted with a pes-
sary. Women were eligible to participate in this study if
they were 18 years or older, confirmed to have prolapse of
any type, of severity stage I to IV (as measured on vaginal
examination using the pelvic organ prolapse quantitation
(POP-Q) method, [27]), and were successfully fitted with a
pessary which was still in place after 2 weeks. Women
were excluded if they had previously had a pessary or been
formally taught PFMT, if there were contraindications to
either of these treatments, or if they were unable to give
informed consent. The women targeted for the pilot trial
had been screened for another trial, for which they had
been ineligible due to the fact they had a pessary fitted. A
patient information leaflet was provided and written
informed consent obtained. Ethical approval for the study
was obtained from the West of Scotland Research Ethics
Committee (REC) 1 on 7 December 2007 (07/S0703/141).
At the appointment when the pessary was fitted,
women were told about the study. If agreeable, women
were then contacted by the study office to discuss their
participation. Consenting participants were randomized
into one of two groups: 1) PFMT (delivered by a special-
ist women’s health physiotherapist at five appointments
over 16 weeks) in conjunction with pessary management
of their prolapse (intervention group); or 2) pessary
management alone (control group). Participants had a
nurse appointment 6 months after randomization at
which time their pessary was removed for 1 month, and
an assessment of vaginal tissues and symptoms wasundertaken. At 7 months after randomization, participants
attended a review appointment with their gynecologist to
have their prolapse re-assessed, the pessary re-fitted if
necessary, and other treatment needs discussed. Parti-
cipants received postal questionnaires at baseline (after
pessary fitted but prior to randomization), 6 months post-
randomization (prior to seeing the nurse to have their
pessary removed), and 7 months post-randomization
(prior to the 7-month gynecologist review appointment),
and recorded symptoms in a diary for 1 month after re-
moval of the pessary at 6 months. The primary outcome of
the pilot trial was prolapse symptoms measured using the
pelvic organ prolapse symptom score (POP-SS) [26]. Other
secondary prolapse outcomes were: prolapse-related quality
of life, prolapse severity (POP-Q) [27], and perceived
change in prolapse since pessary fitted. POP-Q assessment
at 7 months was undertaken blind to the group allocation
and previous POP-Q results.
Analysis methods
No systematic guidance on how to categorize and ex-
plore issues that have arisen in a feasibility study was
identified. However, Shanyinde et al. [15] reported 14
issues that need to be evaluated in feasibility studies or
pilot trials. Shanyinde et al. were not completely clear
on how those 14 issues were developed; however, some
issues may have arisen from the detailed literature review
they had undertaken, and all appear to have a degree of
face validity. We used the list of 14 methodological issues
(as the best available) to categorize and assess the extent
to which each issue was addressed (or not) in this feasibil-
ity study with pilot trial. Subsequently, we developed a
process to support robust and systematic decision-making
in moving from feasibility study to full trial and on to real-
world implementation. The feasibility and pilot data from
the exemplar study were examined in order to address
issues highlighted by using the Shanyinde et al. methodo-
logical issues as a framework [15], and to test out the
newly-developed process. Pilot trial data were analyzed
using descriptive statistics, but no statistical testing was
undertaken as the study did not aim to draw inferences
from the data.
Results
The results of applying the methodological issues as an
analytic framework [15] to the exemplar study findings
are presented under each of the 14 items summarized in
Table 1.
Sample size calculation
The number of participants recruited in the pilot trial
was small (n = 16 out of the target of 50 participants);
indeed, poor recruitment was a key issue within the
study. The sample size for a potential main trial was,
Table 1 Summary of findings against 14 methodological issues for feasibility research
Methodological issues Findings Evidence
1. Did the feasibility/pilot study
allow a sample size calculation
for the main trial?
Achieved even though sample
was small
16 out of target of 50 participants achieved
in feasibility study
103 per group indicated for main trial
2. What factors influenced eligibility
and what proportion of those
approached were eligible?
Ineligibility for randomization was
mainly due to participant refusal
31 out of 66 approached were eligible
3. Was recruitment successful? Recruitment was very difficult. Issues
at center, clinician, and participant levels
Centers showed low enthusiasm.
Clinicians failed to identify participants
Eligible participants not willing to take part
(11/31 withdrew pre-randomization)
4. Did eligible participants consent? Low conversion to consent 16 (52%) randomized out of 31 eligible
participants
5. Were participants successfully
randomized and did randomization
yield equality in groups?
Worked well Equal sized groups, well-balanced on the
minimization variables
6. Were blinding procedures
adequate?
Where used, blinding worked well Self-reported evidence from gynecologists
suggests blinding of POPQ measurement
was successful
7. Did participants adhere to the
intervention?
Good adherence to PFMT appointments
and less so to diaries
Physiotherapy appointments attended: n = 5,
62.5%; n = 4, 12.5%; n = 3, 12.5%; n = 2, 12.5%
Exercise diaries returned: n = 4, 50%;
n = 3, 25%; n = 2, 12.5%; n = 0, 12.5%
8. Was the intervention acceptable
to the participants?
Not directly assessed but low numbers
recruited suggest some difficulty
15 eligible participants decided not to be
randomized once all information was available
9. Was it possible to calculate
intervention costs and duration?
Assessed in the linked trial Cost of PFMT: £170 for mean of 4.2
appointments attended
10. Were outcome assessments
completed?
Outcome measures used did
assess main areas of interest
See summary of outcome data in Table 2
11. Were outcomes measured those
that were the most appropriate
outcomes?
Sexual problems questionnaire
completion poor
Only 25% of participants completed all
items at baseline
12. Was retention to the study
good?
Once recruited retention was good Response rates:
6-month questionnaire: 100% I, 87.5% C
7-month questionnaire: 75% I, 37.5% C
Symptom diary completion: 62.5% I, 37.5% C
6-month appointment: 87.5% I, 50% C
7-month appointment: 75% I, 37.5% C
Agreed to pessary removal: 66.7% I, 33.3% C
13. Were the logistics of running
a multicenter trial assessed?
Some centers recruited better than
others. The center that recruited well
had a dedicated local recruiter
Center 1: 15 participants (dedicated recruiter)
Center 2: 1 participant
Center 3: 0 participants
Center 4: 0 participants
14. Did all components of the
protocol work together?
Components had strong synergy There were no difficulties identified in the
various processes and the researcher’s ability
to implement them. For example, if participants
were recruited, they were easily randomized
and their care moved forwards to the
appropriate trial arm.
Methodological issues based on Shanyinde et al. [15]. C, control; I, intervention; PFMT, pelvic floor muscle training; POP-Q, pelvic organ prolapse quantitation.
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groups in the primary outcome measure observed at 6
months. It was estimated that a future trial powered to
detect the observed difference (3 points on the POP-SS,
SD 7) would require 103 participants per group (90%
power, 5% level of significance, two-sided). Our work on
developing the POP-SS instrument, which is based on
women undergoing surgery or PFMT, has given a pre-
liminary estimate of the minimally important change in
POP-SS score of 1.5 [28]. Therefore, as women with
pessary treatment may be different from those on whom
original testing was undertaken, we have chosen a
conservative estimate POP-SS score of 3 between groups
to ensure the difference is meaningful. Given the small
sample size indicated, the question remains: are the
observed difference between groups and SD good indica-
tors on which to base such calculations? Our other stud-
ies using the POP-SS suggest that the SD differs between
populations: treatment naive participants with prolapse
in a trial of PFMT, SD 6; participants after surgery for
prolapse, SD 8; and participants without prolapse in a
longitudinal study of symptoms after childbirth, SD 3.5.
This would suggest that the SD observed in this feasibil-
ity study was in keeping with that in other groups of
participants known to have a prolapse. If the SD was
artificially inflated the impact on sample size calculations
would be to increase the sample size, thus providing an
overestimate of what was needed. Establishing the differ-
ence between groups in the primary outcome measure is
of course the aim of the main trial and cannot be accur-
ately estimated in a small sample. Examining estimates
of effect size from other studies which have measured
the same outcome can also help to inform the main trial
sample size.
Eligibility
During the period from 1 February 2008 to 11 February
2010, a total of 66 women were approached to take part
(Figure 1, Consolidated Standards of Reporting Trials
(CONSORT) diagram). Of these, 24 women were ineli-
gible mainly due to being unwilling to be contacted by
the study team after being provided initial information
by clinical staff (n = 20). Of the 42 eligible women, 11
did not successfully retain their pessary so became ineli-
gible. A further 15 women either decided not to partici-
pate when the study office contacted them to obtain
consent, or withdrew once they received paperwork
prior to randomization. The remaining 16 participants
were randomized, eight to intervention and eight to the
control group.
Recruitment
Recruiting to the study proved very difficult, despite an
extended recruitment period and the addition of anextra center. Three centers effectively failed to initiate
recruitment. Reasons given by those centers included
extremely busy clinics and limited use of pessaries by
the recruiting gynecologists. In addition, many women
were reluctant to participate as noted above. As women
were recruited at a point when the decision to fit a pes-
sary had already been made, this may have affected their
motivation to agree to being randomized to receive an
additional intervention.
For a considerable number of women, not taking part
in the study seemed linked to the fact that they saw the
pessary as a permanent solution; if the pessary relieved
their symptoms they would keep it in the long-term and
there would be no need for additional intervention. One
of the hypotheses, however, was that the combination
of PFMT and pessary might allow women to become
symptom-free, or have reduced symptoms, without the
need for a pessary. Thus, to be recruited, women needed
to view the pessary as potentially a short-term compo-
nent of their treatment. The fact that some women did
not wish to have their pessary removed at 6 months
indicates that this was not always the case.
There was an indication that participants who entered
the study were younger and had less severe prolapse
than those who did not. This perhaps suggests that the
older participants with more severe prolapse favored a
pessary on a more permanent basis and therefore were
less inclined to take part.Consent
Of the 66 women approached by their gynecologist to
take part, 20 were unwilling at the outset to be con-
tacted by the study team, and prior to randomization a
further 15 women decided not to participate. Thus, over
half of the women approached and otherwise eligible
chose not to consent to take part. Better counseling of
women by clinical staff at study centers may have
avoided this problem. In the center where there was a
dedicated person undertaking screening, gaining consent
was more successful.Randomization procedures
Once participants had completed and returned their
consent form their group allocation was determined.
The research assistant randomized participants into one
of the two groups using a randomization programme in
Access (Microsoft, Redmond, WA, USA) developed by
the Centre for Healthcare Randomized Trials (CHaRT),
University of Aberdeen, Aberdeen, UK. Randomization
was minimized on center, stage of prolapse (I, II, III, IV),
type of pessary fitted (ring or shelf ), and whether topical
estrogen was being used (yes, no). The processes for
achieving randomization worked smoothly.
66 Women Approached
Number ineligible n=24
Number eligible 
n=42
Number randomised n=16
Intervention    
n= 8
Control  
n= 8
Withdrew n=1 Withdrew n=4
Pre-Randomisation 
Withdrawal:
Pessary fell out n=11
Changed mind n=15
Reasons for ineligibility*:
Unwilling to be contacted n=20
On waiting list for surgery n=6
Preference for PFMT n=4
Previous surgery n=2
Previous PFMT n=2
Other n=7
*women may have multiple reasons for 
withdrawal/ineligibility
Numbers for analysis, intervention 
group:
Number returning 6 month 
Questionnaire n=8 
Number attending 6 month nurse 
appointment n=7
Number agreeing to have pessary 
removed for 4 week period n=6
Number returning symptom diary 
n=5
Number returning 7 month 
questionnaire n=6
Number attending 7 month review 
with gynaecologist n=6
Numbers for analysis, control group:
Number returning 6 month 
Questionnaire n= 7
Number attending 6 month nurse 
appointment n=4
Number agreeing to have pessary 
removed for 4 week period n=3
Number returning symptom diary 
n=3
Number returning 7 month 
questionnaire n=3
Number attending 7 month review 
with gynaecologist n=3
Figure 1 CONSORT diagram.
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Blinding of participants and the intervention physiother-
apists was not possible given the nature of the interven-
tion. However outcome assessment was mainly through
participant-completed questionnaires, thus avoiding as-
sessor bias. Gynecologists were blinded to participants’
group allocation at the 7-month follow-up prolapse re-
view appointment.
Adherence to intervention
Adherence in terms of replying to study questionnaires
was high at baseline and 6 months, but at 7 months was
poorer, particularly in the control group. Attendance at the
6-month nurse appointment and the 7-month gynecology
review appointment was poor in the control group.Adherence with attending physiotherapy appointments
was good, with 75% of participants in the intervention
group attending four or five of the planned five appoint-
ments, and all except one participant completed the exer-
cise diaries between appointments.
Acceptability of intervention
Acceptability was not assessed directly but adherence to
physiotherapy gives an indication, as does the initial
(poor) rates of willingness to participate. It may be that
the intervention and the trial processes were acceptable
to some participants (those that participated and ad-
hered to the protocols) but not others (those who chose
not to take part, perhaps due to being put off by the
intervention or the associated trial processes, or by
Table 2 Summary of primary outcome (POP-SS) and main
secondary outcomes at baseline, 6 months, and 7 months
POP-SS score (scores presented
as mean (SD) median, range, n)a
Intervention Control
Baseline 4.57 (3.87) 3.00 (2.20)
3, 2 to 13 3, 1 to 8
n = 7 n = 8
6 months 5.38 (4.72) 8.57 (9.65)
4, 1 to 14 4, 1 to 28
n = 8 n = 7
7 months 15.33 (6.35) 12.67 (9.24)
19, 8 to 19 18, 2 to 18
n = 3 n = 3
Change in POP-Q stageb n = 6 n = 3
+ 2 stages 0 0
+ 1 stage 2 (33%) 2 (66%)
No change in stage 3 (50%) 1 (33%)
−1 stage 0 0
−2 stages 1 (17%) 0
How do you feel your prolapse
is now compared to when your
pessary was first inserted?
6 months n = 7 n = 7
Better 5 5
Same 2 1
Worse 0 1
7 months n = 6 n = 3
Better 3 1
Same 2 1
Worse 1 1
aPOP-SS score: 0 = none, 28 = all symptoms all the time; ba negative value
indicates an improvement at 6 months. POP-SS, pelvic organ prolapse
symptom score; POP-Q, pelvic organ prolapse quantitation.
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were common in the control group suggesting that con-
trol participants may have been dissatisfied with their
allocation.
Cost and duration of intervention
No economic evaluation was included in the study but
cost information was available from a related trial about
cost of PFMT [29].
Outcome assessment
The participants mainly had prolapse involving the anter-
ior vaginal wall, of stage II or III severity. Of the 16 partici-
pants randomized, five withdrew post-randomization (one
intervention and four control participants) for various rea-
sons; however, four of these participants continued to
complete questionnaires. Two participants did not wish
their pessary to be removed at the 6-month stage. Seven-
month POP-Q data were available for nine participants.
The randomized groups were comparable at baseline
with regard to demographic and outcome variables. The
mean age of participants who were not randomized was
slightly older (70.52 years, SD 13.56, n = 40) compared
to those randomized (63.12 years, SD 14.301, n = 16)
suggesting a slight selection bias towards younger
women participating in the study (t = 1.817, df = 54, P =
0.075). Non-randomized participants also tended to have
more severe prolapse (stage I, 0%; stage II, 60%; stage
III/IV, 40%) compared to randomized participants (chi-
squared test = 10.920, df = 2, P = 0.004).
The mean POP-SS score was greatest (more frequent
symptoms) in both groups at the 7-month time-point,
indicating worse symptoms after the pessary had been
removed (Table 2). The mean score was higher in the
control group compared to the intervention group at 6
months, but the reverse was true at 7 months.
Comparable changes in POP-Q stage were observed in
the intervention and control group (Table 2). There was
no difference between the study groups in terms of the
subjective change in prolapse that participants reported
in the 6- and 7-month questionnaires (Table 2).
Selection of most appropriate outcomes
The most appropriate outcomes to use were decided be-
forehand based on the experience of the researchers in
other prolapse studies [26,29-31]. However, response to
the sexual symptom questionnaire was poor with some
participants finding these questions intrusive.
Retention
Information on follow-up questionnaire rates is included
under the adherence section. Once participants were
randomized follow-up was generally good, both in terms
of attendance at appointments and completion ofquestionnaires, suggesting that this part of the method-
ology would be transferrable to a larger trial. Adherence
did appear to be poorer in the control group, and com-
ments from some participants suggested that this was
because they considered they were ‘missing out’ due to
their allocation to the control group.
Logistics of multicenter trial
Some centers failed to recruit, suggesting that there may
be some difficulty with implementing a multicenter trial.
The center that recruited the majority of participants
had dedicated local researchers responsible for local trial
operationalization and recruitment.
All components of the protocol work together
Undoubtedly, we gained experience of delivering the
various components contained within a protocol that
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This was the main strength of running the trial on a
small scale beforehand, which was a miniature version of
the (then) planned main trial.
Discussion
Despite some aspects of the pilot study running relatively
smoothly (for example, randomization and general adher-
ence), data revealed the existence of a number of feasibility
issues in designing and operationalizing a full trial. These
included problematic center/clinician engagement, low
initial patient willingness to participate, significant drop
outs post-consent but pre-randomization, introduction of
potential selection bias at recruitment, and low levels of
data completion with regard to exercise diaries.
Methodological choices, challenges, and trade-offs in
responding to the feasibility results
Given the issues outlined, we concluded that the trial
was not feasible in its current form. The study did sug-
gest that issues such as randomization, blinding, adher-
ence to the intervention, outcome assessment, retention,
and all components working together were reasonably
non-problematic. In addition, sufficient data was ob-
tained to inform a sample size calculation. However, a
number of important changes would also need to be
made: we lacked information about the population to
whom this intervention may be best targeted towards,
mainly in terms of acceptability; despite some helpful
studies of pessary use [19,32,33] we lacked information
about use of pessaries by clinicians (recruitment); we
identified that recruiting post-pessary treatment decision
was probably not the best strategy (eligibility/recruit-
ment/consent); we identified the need to change to using
dedicated local recruiters (recruitment/consent); con-
temporary evidence published after the start of the feasi-
bility study also suggested a third arm to the trial should
be added (intervention); and one outcome was poorly
completed and needed reconsideration (outcomes).
Consideration of the challenges highlighted by the feasi-
bility study revealed two principle methodological chal-
lenges: 1) deciding what to change in the light of the pilot
study findings (the intervention, the trial design, and/or
the clinical context) and the implications of those changes
for the explanatory or pragmatic nature of the trial; and 2)
a lack of formal or informal guidance on how decision-
making in response to pilot trial findings should be made
and/or documented. These are explored in turn below.
How should decisions regarding what to change as a
result of the findings of a pilot RCT be made?
We identified four potential options in regard to ad-
dressing the problems identified: 1) adapting the inter-
vention; 2) adjusting the clinical context within whichthe intervention would be delivered; 3) amending ele-
ments of the trial design; or 4) a combination of any of
the former (Figure 2). We soon found that many of the
problems identified in the feasibility study could be ad-
dressed by targeting any or all of the above. However,
further consideration revealed that some solutions may
solve the problems for the trial, but would not work sub-
sequently in the ‘real-world’, thereby storing up the prob-
lem for later implementation. Below we demonstrate
this in regard to recruitment.
If we assume that problems faced around recruitment
of participants stemmed largely from a lack of accept-
ability of the intervention, then a challenge is imme-
diately faced. Given the fundamental nature of the
intervention, including its relative simplicity, there were
few parameters that are open to adaptation. One might
be the use of financial incentives to aid recruitment and
even adherence. Certainly, this is gaining increasing
popularity in regard to a range of health and illness
behaviours [34,35] and is showing some degree of effect-
iveness, at least within the short-term [36,37]. The deci-
sion to use incentives is methodologically acceptable and
compatible with an explanatory trial. Demonstrating
potential benefit is central to such trials and as such ne-
cessitates strong study control and maximizing high
patient adherence [13,38]. Indeed, Thorpe et al. argued
that ‘the more rigorous a trial is in measuring and
responding to noncompliance of the study participants,
the more explanatory it becomes’ [39], p.54. However,
we had originally intended the purpose of the final trial
to be largely pragmatic, demonstrating potential real-
world benefit and thereby providing helpful information
for both policy makers and clinicians in their decision-
making processes [40]. In order to achieve this, the
benefit and feasibility of the intervention must be dem-
onstrated in real-world conditions. With regard to ad-
herence, Godwin et al. [12] suggested that this means
that attempts can be made to improve compliance, but
these must not go beyond what would be expected in
routine practice. We are therefore left with two apparent
choices: to use incentives to increase recruitment and
adherence but provide results from a final trial that are
inapplicable to the real-world, or not to use incentives
and to conduct a pragmatic trial that is likely to show
effectiveness despite potential benefits (if only partici-
pants would adhere).
Despite this apparent tension, we would argue a third
option exists: to redefine incentives as an added parameter
of the intervention rather than representing a change to
context/routine clinical practice. This means increasing
the complexity of the intervention based on empirical data
within the feasibility study; the intervention now has two
components: pessary and incentive. If defined as such then
the benefits of external validity (generalizability), the
TYPE A: Issue likely to 
be a problem ONLY FOR 
THE TRIAL (i.e. unlikely 
to be a problem in the 
real world)
TYPE B: Issue is likely to 
be a problem for BOTH 
THE TRIAL AND THE 
REAL WORLD
TYPE C: Issue is likely to 
be a problem 
ONLY FOR THE REAL 
WORLD
EVIDENCE:
EVIDENCE:
EVIDENCE:
PROBLEM TYPE SOLUTIONS
CHANGE ASPECTS OF:
a) INTERVENTION
1)
2)
3)
b) TRIAL DESIGN
1)
2)
3)
c) CONTEXT
1)
2)
3)
ASSESSMENT OF SOLUTIONS
CHANGE ASPECTS OF:
a) INTERVENTION
1)
2)
3)
b) TRIAL DESIGN
1)
2)
3)
c) CONTEXT
1)
2)
3)
Could solution be effective in trial setting?
yes no
Could solution be feasible in trial setting?
EVIDENCE:
EVIDENCE:
yes
no
Could solution be effective in real world?
yes
EVIDENCE:
EVIDENCE:
Could solution be feasible in real world?
yes
no
no
EVALUATION OF SOLUTIONS
Box 1: Trial Context
Stage 1: Rank options by likely
degree of effectiveness and 
feasibility– in the trial.
Stage 2: Assess potential to combine 
solutions considering any likely 
interaction in terms of feasibility and 
effectiveness- in the trial.
Stage 3: Assess the most cost-
effective single or multiple solution –
in the trial.
Box 2 Real World Context
Stage 1: Rank options by likely 
degree of effectiveness and 
feasibility– in the real world.
Stage 2: Assess potential to combine 
solutions considering any likely 
interaction in terms of feasibility and 
effectiveness- in the real world.
Stage 3: Assess the most cost-
effective single or multiple solution –
in the real world.
In order to maximise external validity 
of the trial prioritise options which 
achieve highly on Box 1 AND Box 2.
IF there is a trade-off in effectiveness 
for any solution(s) between Box 1 and 
Box 2 then:
• For a more explanatory trial 
prioritise Box 1
• For a more pragmatic trial 
prioritise Box 2
Figure 2 A process for Decision-making after Pilot and feasibility Trials (ADePT).
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ence from the trial and that benefit stems from pessary
use plus incentives within routine clinical practice rather
than pessary alone. The inclusion of additional interven-
tion parameters in order to address contextual weaknesses
is not new, and may more commonly be included as the
educational component required for clinicians to fully
engage with and deliver the intervention [41]. If the added
parameter is financial, it may be beneficial to consider eco-
nomic evaluation within feasibility work, particularly in
the context of pragmatic trials.
Pragmatic trials are known to frequently test interven-
tion ‘strategies’ rather than simple devices per se, allow-
ing greater clinician and patient discretion with regard
to the adoption and use of the intervention [38]. How-
ever, the current literature on explanatory versus prag-
matic trials has not adequately addressed the question as
to how or when such a strategy is developed or decided
upon, nor has the literature on feasibility and pilot stud-
ies. The 2000 version of the MRC framework for com-
plex interventions suggests a linear process in whichfeasibility and pilot testing are conducted after a period
of modeling and intervention definition, thus the inter-
vention is largely defined [42,43]. This study, however,
suggests that the process of intervention development
and definition may well continue post-feasibility and
pilot. This is certainly more akin to the less linear and
more iterative process included in the updated 2008
framework [1].Can guidance to support evidence-based and
documented decision-making in response to pilot RCT
findings be produced?
The final methodological problem that we faced was the
lack of any detailed guidance to support the complex
decision-making required, and there did not appear to be
any requirement to make the alternative amendments,
their consequences, or the rationale for the final choice
explicit to external audiences. At the heart of any such
guidance must be the assurance that the endpoint will be
a trial design that is fit for purpose [13].
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greater rigor at this stage of the intervention and trial
design process, the final utility, through real-world ef-
fectiveness and likelihood of real-world implementation,
will be significantly enhanced. Several authors have
highlighted that funders have historically preferred the
rigor and internal validity offered by explanatory trials
[44]. Certainly, this is the case for pharmaceutical com-
panies where the explanatory trials are likely to show
larger effect sizes for more narrowly defined patients
within more controlled circumstances. However, the
move towards more pragmatic trials has been largely
fuelled by an increasing willingness to apply RCT
methods to more complex interventions (which natur-
ally tend to be less well-defined [45], more flexible [46],
and more context-dependent [45]), and a recognized
need to provide information of greater utility to policy-
makers, clinicians, and patients [40,47,48]. If utility to
stakeholders is a likely criterion of success then it would
seem that their perspectives would need to be taken into
account when assessing the varied strategies that might
be adopted in response to problems highlighted by feasi-
bility studies. Again, this suggests not only that current
guidance on criteria that feasibility and pilot studies
should address might benefit from expansion, but also
the process of suggestions and recommendations about
decision-making processes as well. It is this gap that A
process for Decision-making after Pilot and feasibility
Trials (ADePT) seeks to fill.
ADePT
Given the tensions highlighted, we sought to establish a
systematic means of supporting and documenting future
decision-making in this area. Consequently, we devel-
oped the ADePT process to: 1) encourage the systematic
identification and appraisal of problems and potential so-
lutions; 2) improve the transparency of decision-making
processes; and 3) reveal the tensions that exist between
pragmatic and explanatory choices. The process is shown
in Figure 2, with a worked example addressing the issue
of acceptability of the intervention to the PEPPY study
shown in Additional file 1. The ADePT process includes
3 key steps.
Step 1: Deciding on the type of problem experienced and
the evidence to support that allocation
Three types of problems are possible: type A, the issue is
likely to be a problem only for the trial (that is, unlikely to
be a problem in the real-world); type B, the issue is likely
to be a problem for both the trial and the real-world; and
type C, the issue is likely to be a problem only for the
real-world.
For each type, it is necessary to expose the evidence
for why the problem exists and what type of problem itis. In the example (Additional file 1), evidence from the
failure to achieve recruitment and from methodological
papers suggest that acceptability of the intervention (the
pessary) was a problem. Furthermore, the intervention
(pessary) is an existent clinical tool and not amendable
to adaptation; therefore, the acceptability issue was
highly likely to be a problem for the trial and also a
problem for the real-world implementation. This typ-
ology is crucial for later decision-making in order to
facilitate the choice of a solution that will not only pro-
vide a short-term solution for the trial but also, if neces-
sary, a longer-term solution that would be possible to
implement in the real-world.
Step 2: Identifying the range of potential solutions and the
evidence to support those solutions
Potential solutions may apply to the intervention, the
trial design, or the clinical context. Solutions can be iden-
tified in various ways, including: literature searching; de-
bate/ brainstorming within the research team (ideally
including lay representation); and, if available, through
analysis of feasibility study data. The documentation of
the identified solutions lays the process open to scrutiny,
and hence debate and transparency. Depending on the
type of problem (type A, B, or C), each solution will need
to be assessed in regard to its ability to address or ameli-
orate the problem in the trial, or real-world clinical con-
text, or both. The assessment of each option should be in
terms of: 1) the potential effectiveness of the solution;
and 2) the potential feasibility of the solution. Evidence to
support each assessment should, ideally, be provided.
In the documented example (Additional file 1) we
assessed solutions through searching the research lite-
rature (focusing on methodological reports and ex-
periences reported within clinical trials), and focused
discussions with colleagues who had experience of simi-
lar issues and/or potential solutions.
Step 3: The assessment of best options
Once all options have been appraised then a final deci-
sion should be made. For type A and type C solutions, a
simple ranking and assessment as to whether a single or
combined solution might be best is likely to suffice; this
may also incorporate an assessment of associated costs.
For type B problems, a final assessment is likely to be
more complex. It is possible that a solution may be iden-
tified that is judged to work extremely well in both the
trial and real-world, in which case this should be chosen
as this option will effectively minimize the tension be-
tween internal and external validity – the explanatory
trial becomes increasingly synonymous with the prag-
matic trial. However, we anticipate that in the majority of
cases a judgment may have been made that some solu-
tions may work extremely well within the trial but will
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situation the research team and others may be forced to
choose where on the continuum of explanatory to prag-
matic [39] they wish to place the trial, and justify this.
We would acknowledge that obtaining robust evidence
to support choices and trade-offs at each of these stages
is likely to prove difficult. However, decisions will have
to be made even if only on tentative evidence or argu-
ment. In other areas facing this dilemma, for example,
the creation of clinical guidelines, forms of consensus
method have been effectively employed [49]. It is pos-
sible that this could be explicitly adopted to improve the
transparency and rigor of stakeholder decision makers
within feasibility studies. Indeed, while Godwin [12] and
others have highlighted the frequent trade-off between
internal and external validity, it is possible that the in-
clusion of wider stakeholders in the generation and as-
sessment of solutions may more effectively identify ways
of achieving both, or at least minimizing trade-off, for
any particular intervention and trial. Documenting and
exposing the decision-making process becomes even
more important when the evidence to support decision-
making is weak, because laying the process bare pro-
motes transparency, robustness, and exposure of the
trade-offs made between a more explanatory and a more
pragmatic design.Conclusions
This feasibility and pilot study successfully gained know-
ledge about the process and implementation of the pro-
posed main trial. It has also identified the gaps in our
knowledge that require to be filled prior to progressing
to a main trial. We have undertaken a further survey of
professional practice to supplement the study [50] and
plan a small qualitative study to explore acceptability to
participants. Although the trial is not feasible in the
tested form, some adaptations and the further studies
will allow us to progress forwards to a stronger main
trial. We advocate the use of Shanyinde et al.’s work to
structure discussion about what has been, or could be
learned, from a feasibility study and where the gaps
remain [15], and testing the ADePT process to support
systematic and transparent identification of issues and
solutions for the design of future trials. Our on-going
work with ADePT will explore its usefulness when
developing an intervention and designing the trial to test
it. The worked example and the identification of trade-
offs between previously unacknowledged options have
raised the question as to whether a pilot RCT should be
conducted to assess the feasibility of an explanatory/
pragmatic trial, or to decide whether it should be ex-
planatory or pragmatic. Further consideration of this
issue is recommended.Additional file
Additional file 1: Worked example using ADePT [51-69].
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